December 14, 2020
AstraZeneca announces $39B acquisition of Alexion
AstraZeneca announced plans to acquire US-based Alexion Pharmaceuticals for $39B on Saturday. Alexion is an immunology-focused pharmaceutical company that focuses on drug development for rare diseases. If completed, the deal would be the largest acquisition in AstraZeneca’s history and among the largest transactions of the year.